Roche’s Elecsys pTau217 blood test secures CE mark for Alzheimer’s

Roche has secured CE mark for the Elecsys pTau217 blood test, developed alongside Eli Lilly, for detecting Alzheimer's disease pathology. The CE mark was granted based on data from retrospective studies in real-world early cognitive decline population. Amyloid pathology is often associated with Alzheimer’s disease. Credit: digicomphoto / Shutterstock.com. Roche has secured CE mark for the Elecsys pTau217 blood test, developed alongside Eli Lilly, for detecting Alzheimer’s disease pathology. The test is designed for measuring the phosphorylated Tau (pTau) 217 protein, a key indicator of amyloid pathology, often associated with Alzheimer’s. Combine business intelligence and editorial excellence to reach engaged…

Source: Medical Device Network